LINC02703: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02703

NCBI ID: G102724165

LINC02703

Other Name(s): Long intergenic non-protein coding RNA 2703, transcript variant X2 | long intergenic non-protein coding RNA 2703 | LINC02703 variant X2

LINC02703: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02703 is a long non-protein-coding RNA (lncRNA) that has been identified in various organisms, including humans. It has a unique feature, which is its ability to interact with protein-coding RNAs, leading to the formation of a complex structure called a RNA-protein interaction (RNA-PIs). This interaction between RNA and protein has been reported in various organisms and has been linked to various biological processes, including cell signaling, development, and disease. Therefore, LINC02703 is a potential drug target or biomarker that can be targeted to modulate various cellular processes.

Drug Target Potential

LINC02703 has been shown to play a role in various cellular processes, including cell signaling, cell cycle progression, and tissue development. It has been shown to interact with various proteins, including the protein encoded by the SLC30F1 gene. This interaction between LINC02703 and SLC30F1 has been shown to regulate the activity of the SLC30F1 gene, which encodes a protein involved in the transport of nucleotides into the cytoplasm.

Studies have also shown that LINC02703 can interact with the protein encoded by the HSP70 gene, which is involved in the regulation of protein-protein interactions and is a potential drug target for various diseases, including cancer.

Biomarker Potential

LINC02703 has also been shown to be involved in various biological processes, including cell signaling, cell cycle progression, and tissue development. Its interaction with various proteins has been shown to regulate the activity of these proteins, which can lead to the formation of cellular organelles, such as mitochondria and endoplasmic reticulum, and can also lead to the formation of aggregates that are harmful to cellular health.

Therefore, LINC02703 is a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. It can be used as a target for small molecules or antibodies that can modulate its interaction with various proteins and improve cellular health.

Conclusion

In conclusion, LINC02703 is a long non-protein-coding RNA that has been identified in various organisms, including humans. Its unique feature is its ability to interact with protein-coding RNAs, leading to the formation of RNA-protein interaction (RNA-PIs). This interaction between RNA and protein has been reported in various organisms and has been linked to various biological processes, including cell signaling, development, and disease. Therefore, LINC02703 is a potential drug target or biomarker that can be targeted to modulate various cellular processes. Its potential as a drug target or biomarker makes it an attractive target for small molecules or antibodies that can modulate its interaction with various proteins and improve cellular health.

Protein Name: Long Intergenic Non-protein Coding RNA 2703

The "LINC02703 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02703 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets